The US Food and Drug Administration (FDA) has approved intramuscular (IM) administration of peginterferon β-1a (Plegridy, Biogen) for patients with relapsing forms of multiple sclerosis (MS). "The new ...
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, ...
Biopharma Theratechnologies (NASDAQ:THTX) Friday announced that a study evaluating an intramuscular (IM) method of administration for its therapy, Trogarzo, did not meet the primary endpoint. "The ...
Results were announced from a phase 3 study evaluating an investigational intramuscular (IM) formulation of ibalizumab-uiyk for the treatment of heavily treatment-experienced adults with ...
First Patient Dosed in Small Pharma’s Phase I Study Exploring Intramuscular Administration of SPL026
LONDON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (DMTTF) (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results